Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's wrong with him comfirming that there hasn't been any diluting of shares since the announcement of the a/s increase to 1B shares since the 10Q dated 19 Nov 2012? He's just comfirming that all the know-it-alls who are claiming the company is diluting shares are putting out false info...which we already knew...but now he has comfirmed it as false info!! So what's so wrong with that?
I dunno...he sounded pretty serious! He posted it in two different posts! LOL
Impressive...40M shares @ .02 = $800,000 investment!! lol
More RBCC news today...AMBS mentioned...
http://ih.advfn.com/p.php?pid=nmona&article=55276334
RBCC Issues Shareholder Letter Celebrating Promising 2013
Rainbow Coral Corp. (OTCBB: RBCC) President and CEO Patrick Brown issued the following open letter to shareholders this morning discussing the company’s success in 2012 and big plans for the future:
Dear Shareholders:
Thank you for helping to make 2012 a huge success for Rainbow Coral Corp. The coming year will be even better, and we’re looking forward to announcing some exciting news that we’re certain will generate buzz and boost shareholder value in 2013.
Before we reveal our big plans for the future, however, let’s take a look back at all we’ve accomplished in 2012—our first full year in business.
One of the most exciting developments this year was the deepening relationship between our company and Amarantus BioSciences. Amarantus is on the cutting edge of biotech innovations, and when our joint venture is finalized, we plan to move forward aggressively toward swift profitability.
Our first priority will be commercialization of Amarantus’ incredible new breakthrough, NuroPro. The test has already completed a Phase 1 human clinical trial. Initiating Phase 2 clinical studies will be tops on our agenda next year. Upon completing Phase 2, NuroPro could begin generating revenue through sales under the Clinical Laboratory Improvement Amendment (CLIA) certification.
Next up will be MANF, the groundbreaking new therapeutic protein that Amarantus is developing to treat Parkinson’s disease and traumatic brain injuries. As the world’s population ages and neurological disorders become more prevalent, this could become a major source of revenue for our company soon. Stay tuned.
As many of us are aware, the cure to deadly diseases such as Parkinson’s, Alzheimer’s, and others could be developed someday soon using new stem cell treatments now being investigated. Thanks to adult stem cell technology, the moral objections to stem cell research are beginning to disappear, indicating a bright future for medical breakthroughs.
This year, our joint venture partner Nano3D BioSciences (n3D) demonstrated the impressive potential of its magnetic-levitation cell culturing system known as the Bio-Assembler. The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing tools.
In 2013, the Bio-Assembler is slated to be put to use in high-profile cancer research at the University of Texas Health Science Center at Houston in the Texas Medical Center. As word spreads about the value this technology brings to stem cell research, we expect to see an explosion in interest from top-flight researchers around the world.
We look forward to your continued support as we plan a tremendous year for RBCC and our shareholders in 2013. The best is yet to come for this company as we strive to grow our business worldwide. Enjoy the holidays, and thank you for being a part of Rainbow Coral Corp.!
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
I saw him...he just got his order filled.
I noticed a lot of selling under the bid.
Another 8-K...More news just released.
Item 8.01. Other Events
On November 27, 2012 Amarantus BioSciences, Inc. released the results of an Independent Academic Study report demonstrating that MANF (mesencephalic astrocyte-derived neurotrophic factor), the Company’s leading drug candidate for treatment for Parkinson’s disease, when administered in the striatum in the ventral midbrain, diffused exceptionally well. The accepted cause of Parkinson’s disease is the death of 70-80% of the dopaminergic (DAergic) neurons in the SNc in the ventral midbrain, which leads to lack of innervation in the striatum. Previous animal model studies directed to Parkinson’s disease have shown that the inability of neurotrophic factors to properly diffuse from the site of delivery has been a key technological impediment to developing new treatments for Parkinson’s disease.
The Independent Study indicates that MANF, the Company’s leading drug candidate, diffuses from the point of delivery in the brain more favorably than GDNF; thus, providing a firm basis for the continue investment in MANF development. The next step in MANF development is clinical studies utilizing a primate model. If those studies are positive, they will be incorporated in the toxicological data of an investigational new drug application package to the FDA to be submitted prior to starting a Phase I/II clinical trial for MANF in the treatment of Parkinson’s disease.
It's currenty 1:39pm in Munich.
It is still listed on the Berlin Market
http://www.boerse-berlin.com/index.php/Shares?isin=US02300Q1058
I'm patiently waiting on this Golden Egg! Only a matter of time, it will turn around and head north!!
Looking forward to a great month and beyond!! Go AMBS!!
Thank you Dr Jerry, for creating your profile on 20 Nov 2012, and making your first and ALL 3 of your only post on AMBS just to provide negative information with no sources to back your comments!!
I'll ensure I take your inputs serious...Guess I had better sell off all my shares first thing Monday morning. I wouldn't want to stuck holding any shares in AMBS when it turns around and heads back up to and beyond .06 enroute to dollarland! I would hate to make some money!!
Happy Easter?? LOL Too much eggnog??
Typical Thanksgiving week trading...Looking forward to next week!!
Bummer! I should have waited a little longer. I bought another $5k about 12:00 CST @ .0433
Oh, I was always under the impression NITE was a wholesaler and was out for themselves.
NITE is determined to keep this from running!
That is Awesome Penny Picks...NOT Awesome Penny Stocks...two different promoters!! I already id'd that last week!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81395996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81396560
This could have been a paid promotion by someone with a vested interest in trying to get the share prices up to cash in...say 1M shares at .05. ??? Or anyone else that may have a strong position and a fat wallet.
Here is the translation...
Are we just in the cave of the lion, we are on messersschneide? Why do the trader sell its shares in 0.04 if yet large with millions invested with 0.10 immediately $ get into? was that all one luftnummer, leave already all the sinking ship and seek to hold we in the moment after a strohalm around us? I have did ask stood in that this, I if possible neutrally tried to analyze the share and the background
The worst probability ahead; in the worst fall are we in a bear would fall run, led one us at the nose, and the share falls on Monday from. a second taglikeme, high rejoiced and fallen gelassen.
Only medically scientifically observes, are already must say have would suffice repeated and be supported it people at the board of amgen or bayer, the cream de la cream of the bioteches industry one, and its remarks to the ambs and manf we to that by nahmhaften foundations, are invited to exclusiven conferences, with a very good kominikation with aktienhaltern. And economically observed we have invested two with million amount to at the board, that paid respectively 0,051 and 0.10, and that its moneys with profit get back become.
I think parked the trader over the weekend its moneys, lecture holds paired the amarantus biosciences with the acceptance first on Monday that in the conference.
Already mentioned ceo has not personally some shareholder informed that the appointment will be on Sunday and Monday. therefore can it be that already at the sontag or Monday in the message early one comes.
The volume decreased, many are on wartemodus, in the next good news whereon we wait everyone, will break out the share probably towards the top.
Technical analysis:
2 year assembles: The share comes had formed of split bereinigt 2 ,75$. kontinuirlichen downtrend with intervening seitwärtsbewegung, at the September 2012 a ground and was tested October the ground again, formed between sep okt a so-called W and followed is would
be that a trend return, the share in the moment in the uptrend. ca 0.20 cents the durchschnittspreis.
3 month assembles: The share is last week formed since sept in the aufwärts trend, in that itself a symetrischer pennant, it is passes a trend best ätiguns formation. it tip to and is would ask breaks out only one the time until the share.
The chart speaks speak an unambiguous: here the erkärung:
Pennant (this text is of www. bullchart. de) resembles the symmetrical triangles because it consist of two converging trend lines. The formation appears in a trend as a very short consolidation and belongs as a tertiary formation to the trend confirmations formations. The converging lines can be symmetrical or can have different angles of inclination (aufwärts-/abwärts). The formation names itself in an upwards trend form into a ball pennant (engl. : Form into a ball Pennant) and in a downward trend bear pennant (engl. : Bear Pennant). Time frame of the pennants appears in a time frame from some days to 4 weeks. Basically a time window should be put bottom by 1-3 weeks.
--------------------------------.
I have high loaded a couple of pictures as an example, hope works it out:
AMBS:
https://chart.cortalconsors.is-teledata.com/module.chart?&LANG=de&COUNTRY=de&ID_NOTATION=47219632&QUALITY=BSD&LOGO=bnp&TYPE_CHART=CANDLE&TIME_SPAN=6M&HIDE_GAPS=1&ID_TYPE_SCALE_AXIS=2&INDICATORS_COLOR1=000000&INDICATORS_COLOR2=00FF00&INDICATORS_COLOR3=0000FF&TYPE_IND5=VOLUME&ID_TYPE_SIZE=2&WITH_EARNINGS=0" />
Course goal 1 day: a) if we under 0.04 fall should be the game past. first of all. probability 10%
b) the share nachbörslich closed on Friday in 0,045 and show not in 0,041 like most chartseiten, will remain that share on Monday not quiet, got out get into will become meet break out is should climb would generate many over the weekend that again. with large probability it in 1-2 towards the top. the latitude on Monday between 0,043 and 0,052, on Tuesday the share over 0.05. that a quantity kauf signale. probability 90% course goal 1-3 months: we go follows therefrom out of ambs its aufwärts trend, test yield would wet will inspire become results published that the course, 0,12-0.15 cent
Ambs has meet accelerate become first before 8 or 9 published that it its ambitions the permission in ODA bzw in FDA. after I mentioned the worst scenarios, should take we also the optimum probability under the magnifying glass: Ambs had announced beginning to these years that the tests and clinical phases are locked until date beginning 2013, ambs itself has produce become recently that with regard to michael j fox foundation published the results at the December. Normally clinical tests and the permission on the part of FDA years, several years last. But over ODA, FDA can its allowances until within of 6 months after proposal accelerate.
In amarantus biosciences, one must reckon also with a kurs explosion:
1) receive have. relations it yes, amgen bayer myerscrubb... 2) joint venture 3) allowance of ODA/FDA
In all three possibilities, the share would be in 1-3$.
Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company ............. today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
..........the recent grant the Company was awarded by the Center of Excellence in Apoptosis Research will allow our scientific team to explore MANF's ...................... Data already pooled from publicly available databases suggests this orphan designation strategy may bear fruit for the Company in the near-term."
The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.[1]
A prime example of a successful strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
To the complete text: http://ih.advfn.com/p.php?pid=nmona&article=54787798
It is am invests like always only my modest opinion. I, I work however with stoploss, verlustrisiko 25% of 0.04 on 0.03 gewinnmöglichkeit 2500% of
0.04 on 1$. averages 0.40$
Wish all also you a restful weekend.
Many times the company will do a reverse split (R/S) to bring the share price up to make it more apealing to other investors and to try to qualify to uplist. And to reduce their a/s and o/s.
The success of the R/S depends on the company. If the company has a true product or true idea with potential for pulling in true revenue and the company continues to promote themselves, then they and the shareholder may see a successful R/S, though not a for sure thing.
If they do an R/S and never promote the company, it will spiral down to no man's land again and the share holder will lose their butts. That is almost a for sure thing!!
They are not going to R/S anytime soon. They just increased their A/S and have not increased their O/S. IMO, it going to be used to obtain additional funding or JVs.
Maybe we will get some end of day bargain buyers that will bring it back up before close!
Oh! I'm not selling!! Watching L2 and the shares being bought off the Bid and the price quickly dropping down, makes me think those who don't like carrying shares over the weekend are getting rid of them. jmo
I guess it's getting to be time for the "hold no shares over the weekend" sell off.
VNDM on the ask at .053 again!! Rrrr
.054s almost gone!!
I agree...hopefully, there will be some good news out of this weekends summit as well, e.g., new big money investors/grants or JVs!!
Let's bottom here and head back up!!
AMBS just hit mid nickels!!
Buckle up and hold on to your seats, the ride has begun!! busted nickels!! WOOT WOOT!
Here comes a nickel!!
LMAO...I think today proved it's gonna be a strong n steady ride up!!
I'm guessing mid .05s tomorrow also. Steady climbs are always better than a straight up shot any day...what goes straight up; usually comes straight down! Gradual climbs show more stability!
I don't so much mind the company pumping the stock the way they did. I don't feel it was done with intentions to dump, otherwise I believe they would have hired someone to do the typical PnD campaign. I do know if I hadn't purchased my shares with unsettled funds that didn't settle until today, I would have been out of this yesterday before it dropped below my entry level. However, I decided to watch how it acted today before selling anything. I liked what I saw today; therefore, I'm still in and haven't sold off any at this time and I'm back above my entry point! So I am green and looking forward to tomorrow! I think we will still see steady climbs for a while!
I was thinking the same thing. It was like the company was doing it's own pump by the staggered timing of news releases to keep the momentum and interest in the ticker to get the share price to a level to seem appealing to any potential private investors. As long as it doesn't tank out and hold itself strong and contunue upward like today...I'm good with that!!
If it is a typo...I sure hope he has it on his calendar correct!! Would hate to see him miss the meeting!! lol
Nice stability today!! I guess all the shorts are gone now! Should start building up true value now!
There is no known cure for Parkinson's disease. The goal of treatment is to control symptoms.
Medications control symptoms, mostly by increasing the levels of dopamine in the brain. At certain points during the day, the helpful effects of the medication often wears off, and symptoms can return.
http://health.nytimes.com/health/guides/disease/parkinsons-disease/overview.html